Truffa et al physical limitations, treatment satisfaction, and disease perception/quality of life. The Rose dyspnea scale has four items to assess the level of a patient’s dyspnea with common activities. The SF-12 is used to assess general health status using the physical and mental components of a larger scale called the SF-36. Finally, the EuroQol-5D is a questionnaire with five items assessing mobility, self-care, usual activities, pain and discomfort, and anxiety/depression.28 Using data from the MERLIN trial, Arnold et al demon- strated that compared with patients without angina, patients with daily angina had at least a two-fold increase in resource utilization, with an incremental cost of $4000 after eight months of follow-up.27 Secondary analyses from the same trial showed that overall there was only a small difference in quality of life between patients treated and not treated with ranolazine, and the greatest benefits of this medication were observed for angina frequency, overall quality of life, and treatment satisfaction on the Seattle Angina Questionnaire among those who had angina prior to the acute coronary syndrome event. Smaller benefits were observed in the SF-12 physical and mental component scores, Rose dyspnea score, and EuroQol-5D measures.28 In another study, a graded relationship was observed between higher angina frequency and health care costs, with costs more than twice as high among patients with daily angina compared with those without angina. No differences in overall medication costs were observed between the angina frequency groups, perhaps because patients with higher angina frequency used more antianginal medications than statins and clopidogrel.27 Conclusion The main goals of treatment of stable angina pectoris are to improve quality of life by reducing the severity and/or frequency of symptoms, to increase functional capacity, and to improve prognosis. Ranolazine has been shown to be a reasonable and safe option for patients who have refractory ischemic symptoms despite the use of usual medications for treatment of angina symptoms, and also provides slightly improved quality of life. Disclosure The authors report no conflicts of interest in this work. References 1. Aslam S, Gray D. Ranolazine (Ranexa) in the treatment of chronic stable angina. Adv Ther. 2010;27(4):193–201. 2. Trujillo TC, Dobesh PP. Traditional management of chronic stable angina. Pharmacotherapy. 2007;27(12):1677–1692. 538 submit your manuscript | www.dovepress.com Dovepress Dovepress 3. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics – 2011 update: A report from the American Heart Association. Circulation. 2011;123(4):e18–e209. 4. Vadnais DS, Wenger NK. Emerging clinical role of ranolazine in the management of angina. Ther Clin Risk Manag. 2010;6:517–530. 5. Norton C, Georgiopoulou V, Kalogeropoulos A, Butler J. Chronic stable angina: Pathophysiology and innovations in treatment. J Cardiovasc Med (Hagerstown). 2011;12(3):218–219. 6. Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC guidelines for sec- ondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006;113(19):2363–2372. 7. Melloni C, Newby LK. Metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary syndromes (MERLIN TIMI-36) study. Expert Rev Cardiovasc Ther. 2008;6(1):9–16. 8. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, Skene A, McCabe CH, Braunwald E. Evaluation of a novel anti-ischemic agent in acute coronary syndromes: Design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial. Am Heart J. 2006;151(6):e1181–e1189. 9. Stone PH, Gratsiansky NA, Blokhin A, Huang IZ, Meng L. Antianginal efficacy of ranolazine when added to treatment with amlodipine: The ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol. 2006;48(3):566–575. 10. Fraker TD Jr, Fihn SD, Gibbons RJ, et al. 2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina: A report of the American College of Cardi- ology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 guidelines for the management of patients with chronic stable angina. J Am Coll Cardiol. 2007;50(23):2264–2274. 11. Coronary angioplasty versus medical therapy for angina: The second Randomised Intervention Treatment of Angina (RITA-2) trial. RITA-2 trial participants. Lancet. 1997;350(9076):461–468. 12. Boden WE, O’Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007; 356(15):1503–1516. 13. Newby LK, Peterson ED. Does ranolazine have a place in the treatment of acute coronary syndromes? JAMA. 2007;297(16):1823–1825. 14. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: The MERLIN-TIMI 36 randomized trial. JAMA. 2007;297(16):1775–1783. 15. Dobesh PP, Trujillo TC. Ranolazine: A new option in the manage- ment of chronic stable angina. Pharmacotherapy. 2007;27(12): 1659–1676. 16. Letienne R, Vie B, Puech A, Vieu S, Le Grand B, John GW. Evidence that ranolazine behaves as a weak beta1- and beta2-adrenoceptor antagonist in the cat cardiovascular system. Naunyn Schmiedebergs Arch Pharmacol. 2001;363(4):464–471. 17. Allely MC, Brown CM, Kenny BA, Kilpatrick AT, Martin A, Spedding M. Modulation of alpha 1-adrenoceptors in rat left ventricle by ischaemia and acyl carnitines: Protection by ranolazine. J Cardiovasc Pharmacol. 1993;21(6):869–873. 18. Zhao G, Walsh E, Shryock JC, et al. Antiadrenergic and hemodynamic effects of ranolazine in conscious dogs. J Cardiovasc Pharmacol. 2011; 57(6):639–647. 19. Chaitman BR, Skettino SL, Parker JO, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol. 2004;43(8): 1375–1382. 20. Estacion M, Waxman SG, Dib-Hajj SD. Effects of ranolazine on wild- type and mutant hNav1.7 channels and on DRG neuron excitability. Mol Pain. 2010;6:35. 21. Siddiqui MA, Keam SJ. Ranolazine: A review of its use in chronic stable angina pectoris. Drugs. 2006;66(5):693–710. Vascular Health and Risk Management 2011:7